Xenetic Biosciences Reports Preclinical Data of Potential Co-Administration of DNase I with CAR T Cells for Melanoma Lung Metastasis
Shots:
- Xenetic highlighted preclinical data evaluating the combination of DNase I with CAR T cells in B16 melanoma murine model of lung metastasis at AACR 2024
- Data showed, DNase I (10mg/kg) with EGFR-CAR T cells significantly reduced metastatic tumor burden, decreased metastatic foci, extended survival, boosted tumor-infiltrating T/CAR T cells by degrading NETs, reduced TME immunosuppression and lowered expression of PD-1 & TIM-3 exhaustion markers
- Additionally, the company is progressing its DNase-based oncology program into P-I for pancreatic & metastatic solid tumors. It further reported the completion of preclinical studies assessing DNase I with CT & immuno-therapies in colorectal cancer and CAR-T therapy
Ref: Xenetic | Image: Xenetic Biosciences
Related News:- Flare Therapeutics Inks Pact with Roche to Develop Small Molecules Targeting Undrugged Transcription Factors in Oncology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
